Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 4/20 | 0.57 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 5/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27238830 | 0.82 | HTT (0.47) | FGFR1HCAR1MAPK1HTTPOLB | |
| SCHEMBL11528755 | 0.82 | FGFR1 (0.63) | FGFR1HCAR1POLBLMNAALDH1A1 | |
| SCHEMBL30846080 | 0.82 | HTT (0.47) | FGFR1HCAR1MAPK1HTTPOLB | |
| SCHEMBL12138417 | 0.80 | HTT (0.56) | FGFR1HCAR1MAPK1HTTCYP11B1 | |
| SCHEMBL29830215 | 0.80 | HTT (0.56) | FGFR1HCAR1MAPK1HTTCYP11B1 | |
| SCHEMBL20032453 | 0.78 | FGFR1 (0.50) | FGFR1MAPK1HTTCYP11B1CYP11B2 | |
| SCHEMBL29484667 | 0.74 | FGFR1 (0.46) | FGFR1MAPK1HTTCYP11B1CYP11B2 | |
| SCHEMBL3417306 | 0.74 | HTT (0.73) | FGFR1HTTPOLBALDH1A1 | |
| SCHEMBL23840275 | 0.74 | FGFR1 (0.58) | FGFR1HTTPOLBALDH1A1 | |
| SCHEMBL7211112 | 0.74 | HTT (0.56) | FGFR1HCAR1HTTPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ALTAVANT SCIENCES GMBH | 2023-09-19 | — | — | US | disclosed |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ALTAVANT SCIENCES GMBH | 2023-09-19 | — | — | US | disclosed |
| US-20210205305-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2021-07-08 | — | — | US | disclosed |
| US-10946018-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES GMBH (CH) | 2021-03-16 | — | — | US | disclosed |
| US-20200237760-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ROIVANT SCIENCES GMBH (CH) | 2020-07-30 | — | — | US | disclosed |
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES GMBH (CH) | 2019-07-16 | — | — | US | disclosed |
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2018-04-05 | — | — | US | disclosed |
| US-9750740-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | Kanos Pharmaceuticals, Inc. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9750740-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | Kanos Pharmaceuticals, Inc. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170095476-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2017-04-06 | — | — | US | disclosed |
| US-20170095476-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2017-04-06 | — | — | US | disclosed |
| US-9512122-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | KAROS PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160096836-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2016-04-07 | — | — | US | disclosed |
| US-9199994-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | KAROS PHARMACEUTICALS, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150080393-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2015-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080393-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | FGFR1 1173/4885HCAR1 30/4885MAPK1 1325/4885 |
| US-20200237760-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | FGFR1 1173/4885HCAR1 30/4885MAPK1 1325/4885 |
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | FGFR1 1173/4885HCAR1 30/4885MAPK1 1325/4885 |
| US-20170095476-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | FGFR1 1173/4885HCAR1 30/4885MAPK1 1325/4885 |
| US-20210205305-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | FGFR1 1173/4885HCAR1 30/4885MAPK1 1325/4885 |
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | FGFR1 1173/4885HCAR1 30/4885MAPK1 1325/4885 |
| US-20160096836-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | FGFR1 1173/4885HCAR1 30/4885MAPK1 1325/4885 |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | FGFR1 1173/4885HCAR1 30/4885MAPK1 1325/4885 |
| US-10946018-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | FGFR1 1173/4885HCAR1 30/4885MAPK1 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.